Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 15/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 12/20 | 0.50 |
| ▸ | CDK1 | P06493 | 12/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 12/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 12/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.50 |
| ▸ | GSK3A | P49840 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248397 | 0.78 | LMNA (0.50) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL4160282 | 0.77 | LMNA (0.82) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL14895916 | 0.77 | HSD17B10 (0.46) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL4156981 | 0.75 | LMNA (0.94) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL31721163 | 0.75 | LMNA (1.00) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL2360729 | 0.75 | LMNA (1.00) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL20602364 | 0.72 | MAPT (0.59) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL20602026 | 0.71 | LMNA (0.56) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL20602008 | 0.71 | LMNA (0.56) | LMNAALDH1A1MAPTMAPK1GSK3B | |
| SCHEMBL14731462 | 0.70 | LMNA (0.55) | LMNAALDH1A1MAPTMAPK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-10-04 | — | — | US | disclosed |
| CN-114173780-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| EP-3897634-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020131573-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | NUREDIS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005841-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458121-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC10A1, SLC47A1 | LMNA 4360/4885ALDH1A1 617/4885MAPT 4110/4885 |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RTCB, RRM2B | LMNA 1237/4885ALDH1A1 3113/4885MAPT 3459/4885 |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | LMNA 4360/4885ALDH1A1 617/4885MAPT 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.